|
Gene: ZNF417 |
Gene summary for ZNF417 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZNF417 | Gene ID | 147687 |
Gene name | zinc finger protein 417 | |
Gene Alias | ZNF417 | |
Cytomap | 19q13.43 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | M0R230 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
147687 | ZNF417 | HCC1 | Human | Liver | HCC | 8.69e-32 | 2.82e+00 | 0.5336 |
147687 | ZNF417 | HCC2 | Human | Liver | HCC | 7.39e-40 | 2.62e+00 | 0.5341 |
147687 | ZNF417 | HCC5 | Human | Liver | HCC | 1.12e-67 | 3.15e+00 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF417 | SNV | Missense_Mutation | novel | c.1190N>T | p.Gln397Leu | p.Q397L | Q8TAU3 | protein_coding | tolerated(0.5) | benign(0.009) | TCGA-58-8390-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZNF417 | SNV | Missense_Mutation | c.936T>G | p.Ile312Met | p.I312M | Q8TAU3 | protein_coding | deleterious(0.03) | possibly_damaging(0.601) | TCGA-60-2724-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | cisplatin | SD | |
ZNF417 | SNV | Missense_Mutation | novel | c.1184N>G | p.Leu395Arg | p.L395R | Q8TAU3 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-85-8288-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZNF417 | SNV | Missense_Mutation | novel | c.384C>G | p.Asn128Lys | p.N128K | Q8TAU3 | protein_coding | tolerated(0.58) | benign(0) | TCGA-85-8666-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZNF417 | SNV | Missense_Mutation | novel | c.32N>T | p.Gln11Leu | p.Q11L | Q8TAU3 | protein_coding | tolerated(0.15) | benign(0.007) | TCGA-85-A511-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
ZNF417 | SNV | Missense_Mutation | novel | c.175N>A | p.Gly59Arg | p.G59R | Q8TAU3 | protein_coding | deleterious(0.04) | probably_damaging(0.931) | TCGA-90-A4ED-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZNF417 | SNV | Missense_Mutation | novel | c.397N>C | p.Ala133Pro | p.A133P | Q8TAU3 | protein_coding | deleterious(0.05) | possibly_damaging(0.69) | TCGA-CN-A63T-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
ZNF417 | SNV | Missense_Mutation | novel | c.979A>G | p.Arg327Gly | p.R327G | Q8TAU3 | protein_coding | tolerated(0.52) | benign(0) | TCGA-CR-7386-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | paclitaxel | PD |
ZNF417 | SNV | Missense_Mutation | novel | c.1117N>T | p.Val373Phe | p.V373F | Q8TAU3 | protein_coding | deleterious(0.02) | possibly_damaging(0.759) | TCGA-M7-A721-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 7 | Unknown | Unknown | SD |
ZNF417 | SNV | Missense_Mutation | c.1558N>C | p.Tyr520His | p.Y520H | Q8TAU3 | protein_coding | tolerated(0.05) | benign(0.05) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |